Christine Katlama

Summary

Country: France

Publications

  1. ncbi Maraviroc plus raltegravir failed to maintain virological suppression in HIV-infected patients with lipohypertrophy: results from the ROCnRAL ANRS 157 study
    Christine Katlama
    INSERM, UMRS 943, Paris F 75013, France UPMC Univ Paris 06, UMRS 943, Paris F 75013, France Department of Infectious Diseases, AP HP, Pitie Salpetriere Hospital, Paris, France
    J Antimicrob Chemother 69:1648-52. 2014
  2. pmc Emerging role of integrase inhibitors in the management of treatment-experienced patients with HIV infection
    Christine Katlama
    Pierre et Marie Curie Université Paris 6, Service de Maladies Infectieuses et Tropicales, Paris, France
    Ther Clin Risk Manag 5:331-40. 2009
  3. pmc Hepatic steatosis in HIV-HCV coinfected patients receiving antiretroviral therapy is associated with HCV-related factors but not antiretrovirals
    Valrie Martinez
    Service de Mdecine Interne et Immunologie Clinique, Assistance publique Hpitaux de Paris, INSERM UMR_S 996, Universit Paris Sud, Hpital Antoine Bclre, 157 rue de la Porte de Trivaux, 92141 Clamart, France
    BMC Res Notes 5:180. 2012
  4. doi Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials
    Christine Katlama
    Universite Pierre et Marie Curie, Paris VI and Hôpital Pitié Salpêtrière, Paris, France
    AIDS 23:2289-300. 2009
  5. doi Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials
    Christine Katlama
    Universite Pierre et Marie Curie, Paris 6, France
    Antivir Ther 15:1045-52. 2010
  6. doi Dolutegravir for the treatment of HIV
    Christine Katlama
    Pierre et Marie Curie University Paris VI, Hospital Pitié Salpêtrière, Department of Infectious Diseases, Paris, France
    Expert Opin Investig Drugs 21:523-30. 2012
  7. doi Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136
    Christine Katlama
    INSERM UMR S 943 and University Pierre and Marie Curie UPMC Paris VI, Paris, France
    AIDS 24:2365-74. 2010
  8. ncbi No benefit of a structured treatment interruption based on genotypic resistance in heavily pretreated HIV-infected patients
    Jade Ghosn
    Department of Infectious and Tropical Diseases, Hospital Pitié Salpêtrière, Paris, France
    AIDS 19:1643-7. 2005
  9. doi Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients
    Diane Descamps
    AP HP, Groupe Hospitalier Bichat Claude Bernard and Université Denis Diderot Paris 7, Laboratoire de Virologie, Paris, France
    J Antimicrob Chemother 63:585-92. 2009
  10. pmc Genotypic resistance analysis of the virological response to fosamprenavir-ritonavir in protease inhibitor-experienced patients in CONTEXT and TRIAD clinical trials
    Anne Genevieve Marcelin
    Department of Virology, Pitie Salpetriere Hospital, 83 Boulevard de l hopital, 75013 Paris, France
    Antimicrob Agents Chemother 52:4251-7. 2008

Collaborators

Detail Information

Publications84

  1. ncbi Maraviroc plus raltegravir failed to maintain virological suppression in HIV-infected patients with lipohypertrophy: results from the ROCnRAL ANRS 157 study
    Christine Katlama
    INSERM, UMRS 943, Paris F 75013, France UPMC Univ Paris 06, UMRS 943, Paris F 75013, France Department of Infectious Diseases, AP HP, Pitie Salpetriere Hospital, Paris, France
    J Antimicrob Chemother 69:1648-52. 2014
    ..Given their potency and their excellent metabolic profile, maraviroc and raltegravir appear to be good candidates for such an approach...
  2. pmc Emerging role of integrase inhibitors in the management of treatment-experienced patients with HIV infection
    Christine Katlama
    Pierre et Marie Curie Université Paris 6, Service de Maladies Infectieuses et Tropicales, Paris, France
    Ther Clin Risk Manag 5:331-40. 2009
    ..The rapid rate of viral decay observed with raltegravir challenges the current understanding of HIV-1 turnover and may open new strategies for long term treatment and management of infected patients...
  3. pmc Hepatic steatosis in HIV-HCV coinfected patients receiving antiretroviral therapy is associated with HCV-related factors but not antiretrovirals
    Valrie Martinez
    Service de Mdecine Interne et Immunologie Clinique, Assistance publique Hpitaux de Paris, INSERM UMR_S 996, Universit Paris Sud, Hpital Antoine Bclre, 157 rue de la Porte de Trivaux, 92141 Clamart, France
    BMC Res Notes 5:180. 2012
    ..In HIV and hepatitis C virus (HCV) coinfected patients, the role of antiretroviral therapy (ART) on hepatic steatosis (HS) remains controversial...
  4. doi Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials
    Christine Katlama
    Universite Pierre et Marie Curie, Paris VI and Hôpital Pitié Salpêtrière, Paris, France
    AIDS 23:2289-300. 2009
    ....
  5. doi Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials
    Christine Katlama
    Universite Pierre et Marie Curie, Paris 6, France
    Antivir Ther 15:1045-52. 2010
    ..The 96-week efficacy and safety of the non-nucleoside reverse transcriptase inhibitor (NNRTI) etravirine were evaluated in the Phase III DUET trials...
  6. doi Dolutegravir for the treatment of HIV
    Christine Katlama
    Pierre et Marie Curie University Paris VI, Hospital Pitié Salpêtrière, Department of Infectious Diseases, Paris, France
    Expert Opin Investig Drugs 21:523-30. 2012
    ....
  7. doi Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136
    Christine Katlama
    INSERM UMR S 943 and University Pierre and Marie Curie UPMC Paris VI, Paris, France
    AIDS 24:2365-74. 2010
    ..Darunavir/ritonavir (darunavir/r) maintenance strategy, in patients with suppressed HIV RNA viremia, is a potential long-term strategy to avoid nucleoside analogue toxicities and to reduce costs...
  8. ncbi No benefit of a structured treatment interruption based on genotypic resistance in heavily pretreated HIV-infected patients
    Jade Ghosn
    Department of Infectious and Tropical Diseases, Hospital Pitié Salpêtrière, Paris, France
    AIDS 19:1643-7. 2005
    ..To evaluate the potential benefits of a tailored antiretroviral treatment interruption with duration based on the observed reversion of resistance mutations...
  9. doi Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients
    Diane Descamps
    AP HP, Groupe Hospitalier Bichat Claude Bernard and Université Denis Diderot Paris 7, Laboratoire de Virologie, Paris, France
    J Antimicrob Chemother 63:585-92. 2009
    ..The aim of the study was to identify a pattern of protease gene mutations associated with the virological response to darunavir/ritonavir-based regimens...
  10. pmc Genotypic resistance analysis of the virological response to fosamprenavir-ritonavir in protease inhibitor-experienced patients in CONTEXT and TRIAD clinical trials
    Anne Genevieve Marcelin
    Department of Virology, Pitie Salpetriere Hospital, 83 Boulevard de l hopital, 75013 Paris, France
    Antimicrob Agents Chemother 52:4251-7. 2008
    ....
  11. ncbi Transmission of multidrug-resistant HIV-1: 5 years of immunological and virological survey
    Constance Delaugerre
    Department of Virology EA3620, Necker Hospital, Paris, France
    AIDS 21:1365-7. 2007
    ..In both cases, infection was caused by CCR5 viruses and no rapid clinical progression to AIDS after primary infection was observed...
  12. doi Structural effects of amino acid variations between B and CRF02-AG HIV-1 integrases
    Isabelle Malet
    UPMC Universite Paris 06, Paris, France
    J Med Virol 80:754-61. 2008
    ..In conclusion, virological response to anti-integrase should be studied carefully, according to the subtype, in clinical trials...
  13. ncbi Efficacy and safety of tenofovir double-dose in treatment-experienced HIV-infected patients: the TENOPLUS study
    Stephanie Dominguez
    Département des Maladies Infectieuses et Tropicales INSERM U720, CHU Pitie Salpetriere, Paris, France
    J Med Virol 79:105-10. 2007
    ..This add-on pilot study supports the concept of double dose tenofovir to virologically overcome the decreased sensitivity of NRTI-resistant viruses. However, the safety of this regimen needs to be considered carefully...
  14. pmc Factors associated with the selection of mutations conferring resistance to protease inhibitors (PIs) in PI-experienced patients displaying treatment failure on darunavir
    Sidonie Lambert-Niclot
    Department of Virology, Pitie Salpetriere Hospital, 83 Boulevard de l hopital, Paris 75013, France
    Antimicrob Agents Chemother 52:491-6. 2008
    ..TPV susceptibility does not seem to be affected by the selection of a DRV resistance mutation...
  15. ncbi Efficacy and safety of ritonavir/indinavir 100/400 mg twice daily in combination with two nucleoside analogues in antiretroviral treatment-naive HIV-infected individuals
    Claudine Duvivier
    Department of Infectious Diseases, Pitie Salpetriere Hospital, Paris, France
    Antivir Ther 8:603-9. 2003
    ..To evaluate the efficacy and tolerability of indinavir/ritonavir (IDV/RTV) 400/100 mg twice daily in combination with two nucleoside reverse transcriptase inhibitors in antiretroviral-naive patients...
  16. ncbi Association of Gag cleavage sites to protease mutations and to virological response in HIV-1 treated patients
    Isabelle Malet
    Laboratoire de Virologie bâtiment CERVI, Hopital Pitie Salpetriere, EA 2387, Universite Pierre et Marie Curie Paris 6, Paris, France
    J Infect 54:367-74. 2007
    ..Moreover, we have evaluated associations between the Gag region sequence and the virological response to Protease Inhibitors (PI)...
  17. ncbi Virological and pharmacological factors associated with virological response to salvage therapy after an 8-week of treatment interruption in a context of very advanced HIV disease (GigHAART ANRS 097)
    Constance Delaugerre
    Department of Virology, Pitié Salpetrière Hospital Paris, Paris, France
    J Med Virol 77:345-50. 2005
    ..These results suggest that pharmacological enhancement might overcome viral resistance and that there is some benefit in adding the activity of several boosted-PIs to improve the response to a salvage regimen...
  18. ncbi Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + n
    Cathia Soulie
    Université Pierre et Marie Curie Paris, UMR S 943, INSERM, U943, Paris, France
    AIDS 23:1605-8. 2009
    ..The NNRTI + protease inhibitor strategy should not be recommended as an antiretroviral first-line regimen, particularly in patients with high viral load at baseline...
  19. ncbi Clinical validation of saquinavir/ritonavir genotypic resistance score in protease-inhibitor-experienced patients
    Anne Genevieve Marcelin
    Department of Virology, Pitie Salpftriere Hospital, AP HP, Universite Pierre et Marie Curie, Paris, France
    Antivir Ther 12:247-52. 2007
    ..To identify a genotypic score for resistance to saquinavir boosted with ritonavir (SQV/r; 1,000/100 mg twice daily)-based regimens in protease inhibitor (PI)-experienced patients...
  20. pmc Comparison of the dynamics of resistance-associated mutations to nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors after cessation of antiretroviral combination therapy
    Marc Wirden
    Department of Virology, INSERM EMI 0214, Pitie Salpetriere Hospital, Paris, France
    Antimicrob Agents Chemother 48:644-7. 2004
    ....
  21. ncbi Resistance mutations before and after tenofovir regimen failure in HIV-1 infected patients
    Marc Wirden
    Department of Virology, Pitie Salpetriere Hospital, Paris, France
    J Med Virol 76:297-301. 2005
    ..The K65R mutation can emerge even with TAMs or L74V. No obvious impact was shown on the TAMs or other NRTI mutations, although a trend towards emergence of some particular mutations was observed...
  22. ncbi Efficacy and safety of adefovir dipivoxil plus pegylated interferon-alpha2a for the treatment of lamivudine-resistant hepatitis B virus infection in HIV-infected patients
    Patrick Ingiliz
    Hepatology Department, Pitie Salpetriere Hospital, Paris, France
    Antivir Ther 13:895-900. 2008
    ..Adefovir dipivoxil (ADV) has shown its efficacy for treating 3TC-resistant (3TC-R) HBV in HIV-coinfected patients. ADV combined with pegylated interferon (PEG-IFN) has never been evaluated in this population...
  23. ncbi MIV-310 reduces HIV viral load in patients failing multiple antiretroviral therapy: results from a 4-week phase II study
    Christine Katlama
    Département des Maladies Infectieuses et Tropicales INSERM E0214, Hopital Pitie Salpetriere, Paris, France
    AIDS 18:1299-304. 2004
    ..MIV-310 (alovudine), a nucleoside reverse transcriptase inhibitor, potently inhibits the replication of highly mutated strains of HIV in vitro. We examined the efficacy of MIV-310 in highly pretreated patients...
  24. pmc Interruption of nonnucleoside reverse transcriptase inhibitor (NNRTI) therapy for 2 months has no effect on levels of human immunodeficiency virus type 1 in plasma of patients harboring viruses with mutations associated with resistance to NNRTIs
    Marc Wirden
    Department of Virology, Pitié Salpêtrière Hospital Department of Pharmacology, Bichat Hospital, Paris, France
    J Clin Microbiol 41:2713-5. 2003
    ..These data suggest that these compounds have lost all of their in vivo antiviral activity in such cases...
  25. ncbi Increase of HIV-1 pro-viral DNA per million peripheral blood mononuclear cells in patients with advanced HIV disease (CD4<200 cells/mm3) receiving interleukin 2 combined with HAART versus HAART alone (ANRS-082 trial)
    Constance Delaugerre
    Department of Virology EA2387, Pitie Salpetriere Hospital, Paris, France
    Antivir Ther 8:233-7. 2003
    ..To assess the effect of interleukin (IL)-2 combined with highly active antiretroviral therapy (HAART) on HIV-1 pro-viral DNA quantification in HIV-1-infected patients with CD4<200/mm3...
  26. ncbi Role of HIV-1 minority populations on resistance mutational pattern evolution and susceptibility to protease inhibitors
    Benedicte Roquebert
    Department of Virology, Pitie Salpetriere Hospital, Paris, France
    AIDS 20:287-9. 2006
    ..These minor species, not detected by standard genotype, may influence PI susceptibility...
  27. doi Initial therapy with nucleoside reverse transcriptase inhibitor-containing regimens is more effective than with regimens that spare them with no difference in short-term fat distribution: Hippocampe-ANRS 121 Trial
    Claudine Duvivier
    AP HP, Groupe Hospitalier Pitie Salpetriere, Service de Maladies Infectieuses et Tropicales, Paris F 75013, France
    J Antimicrob Chemother 62:797-808. 2008
    ..The aim of this study was to evaluate the impact on body fat of nucleoside reverse transcriptase inhibitor (NRTI)-sparing regimens compared with NRTI-containing therapy in HIV-1-infected antiretroviral (ARV)-naive patients...
  28. doi Historical HIV-RNA resistance test results are more informative than proviral DNA genotyping in cases of suppressed or residual viraemia
    Marc Wirden
    Department of Virology, Pitie Salpetriere Hospital, 83 bvd de l Hôpital, 75013 Paris, France
    J Antimicrob Chemother 66:709-12. 2011
    ..Analyses of proviral HIV-DNA can provide information about the viral reservoir, because integrated DNA reflects both actively and latently infected cells...
  29. doi Factors associated with virological failure in HIV-1-infected patients receiving darunavir/ritonavir monotherapy
    Sidonie Lambert-Niclot
    Department of Virology and Infectious Diseases, AP HP, Pitie Salpetriere Hospital, INSERM U 943 and Pierre et Marie Curie University, Paris, France
    J Infect Dis 204:1211-6. 2011
    ..Our objective was to determine virological and clinical characteristics associated with virological failure in human immunodeficiency virus (HIV)-infected patients switching to darunavir/ritonavir (DRV/r) monotherapy...
  30. ncbi HIV-1 X4/R5 co-receptor in viral reservoir during suppressive HAART
    Cathia Soulie
    Department of Virology EA2387, Pitie Salpetriere Hospital, University Pierre et Marie Curie, Paris, France
    AIDS 21:2243-5. 2007
    ..This suggests that CCR5 antagonist activity should not be compromised in patients harbouring R5 viruses before starting HAART...
  31. ncbi Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure
    Anne Genevieve Marcelin
    Department of Virology, Pitié Salpêtrière Hospital and University Paris VI Pierre et Marie Curie, Paris, France
    J Med Virol 72:162-5. 2004
    ....
  32. ncbi Genetic barriers for integrase inhibitor drug resistance in HIV type-1 B and CRF02_AG subtypes
    Almoustapha Issiaka Maiga
    Department of Virology, Pitie Salpetriere Hospital, AP HP, EA 2387, Universite Pierre et Marie Curie, Paris, France
    Antivir Ther 14:123-9. 2009
    ..The genetic barrier for IN inhibitor resistance was compared between HIV-1 subtype B and HIV-1 subtype CRF02_AG, which is highly prevalent in West Africa and becoming more frequent in developed countries...
  33. doi Resistant minority species are rarely observed in patients on darunavir/ritonavir monotherapy
    Sidonie Lambert-Niclot
    AP HP, Pitie Salpetriere Hospital, INSERM U 943 and Pierre et Marie Curie University, Paris, France
    J Antimicrob Chemother 67:1470-4. 2012
    ....
  34. ncbi Raltegravir as functional monotherapy leads to virological failure and drug resistance in highly treatment-experienced HIV-infected patients
    Fabienne Caby
    Service des Maladies Infectieuses et Tropicales, Assistance Publique Hopitaux de Paris, Groupe Hospitalier Pitie Salpetriere, Paris, France
    Scand J Infect Dis 42:527-32. 2010
    ..If persistent low viraemia is observed over more than 48 weeks without the emergence of resistance, RAL should never be given as functional monotherapy, as it is associated with a maximal risk of VF and the emergence of RAL resistance...
  35. ncbi Raltegravir has no residual antiviral activity in vivo against HIV-1 with resistance-associated mutations to this drug
    Marc Wirden
    Department of Virology, AP HP, Pitie Salpetriere Hospital, 83 Boulevard de l hopital, Paris, France
    J Antimicrob Chemother 64:1087-90. 2009
    ..We determined whether raltegravir retains residual antiretroviral activity in vivo against viruses harbouring raltegravir mutations, and thus whether the drug can contribute to the subsequent regimen...
  36. pmc Risk factors for selection of the L74I reverse transcriptase mutation in human immunodeficiency virus type 1-infected patients
    Marc Wirden
    Department of Virology, Pitie Salpetriere Hospital, 75013 Paris, France
    Antimicrob Agents Chemother 50:2553-6. 2006
    ..L74I was strongly associated with T215F, K70R, and V75M/S/T/A mutations and increased with the number of thymidine analog mutations. It seemed to be linked to the use of abacavir or efavirenz...
  37. doi A randomized trial of two-drug versus three-drug tenofovir-containing maintenance regimens in virologically controlled HIV-1 patients
    Pierre Marie Girard
    Service des Maladies Infectieuses et Tropicales, Hopital Saint Antoine, Assistance Publique Hopitaux de Paris, Universite Paris VI, Paris, France
    J Antimicrob Chemother 64:126-34. 2009
    ..To assess simplified maintenance regimens containing dual antiretroviral drugs in patients with controlled human immunodeficiency virus type 1 infection...
  38. ncbi Resistance profiles observed in virological failures after 24 weeks of amprenavir/ritonavir containing regimen in protease inhibitor experienced patients
    Anne Genevieve Marcelin
    Department of Virology, Pitie Salpetriere Hospital, Paris, France
    J Med Virol 74:16-20. 2004
    ..There was no relation between the resistance pathways selected with either APV or ritonavir plasma minimal concentration, but higher APV plasma minimal concentration were associated with a lower rate of resistance mutations selection...
  39. doi Impact of gag mutations on selection of darunavir resistance mutations in HIV-1 protease
    Sidonie Lambert-Niclot
    UPMC Univ Paris 06, EA 2387, F 75005, Paris, France
    J Antimicrob Chemother 62:905-8. 2008
    ..To search for genetic factors in the protease and gag regions (NC-p1/TFP-p6/p6pol) involved in selection of darunavir resistance mutations...
  40. doi Impact of hepatitis C and liver fibrosis on antiretroviral plasma drug concentrations in HIV-HCV co-infected patients: the HEPADOSE study
    Stephanie Dominguez
    AP HP, Département de Maladies Infectieuses et Tropicales, INSERM U720, CHU Pitie Salpetriere, Paris, France
    J Antimicrob Chemother 65:2445-9. 2010
    ..To compare plasma antiretroviral concentrations in HIV-HCV co-infected and in matched HIV mono-infected patients...
  41. pmc Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro
    Isabelle Malet
    Laboratoire de Virologie, Hopital Pitie Salpetriere, Assistance Publique Hopitaux de Paris, EA 2387, Universite Pierre et Marie Curie Paris 6, Paris, France
    Antimicrob Agents Chemother 52:1351-8. 2008
    ..These mutations led to strong impairment of enzymes in vitro in the absence of raltegravir: strand transfer activity was affected, and in some cases 3' processing was also impaired...
  42. doi Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study
    Roland Landman
    Service des Maladies Infectieuses et Tropicales, AP HP, Groupe Hospitalier Bichat Claude Bernard, Paris, France
    J Antimicrob Chemother 64:118-25. 2009
    ..We evaluate the efficacy and tolerability of ritonavir-boosted dual protease inhibitor as a nucleoside reverse transcriptase inhibitor-sparing regimen in a prospective open-label randomized pilot trial in antiretroviral-naive patients...
  43. ncbi HIV drug resistance after the use of generic fixed-dose combination stavudine/lamivudine/nevirapine as standard first-line regimen
    Anne Genevieve Marcelin
    Pitie Salpetriere Hospital, Paris, France
    AIDS 21:2341-3. 2007
    ..This highlights the importance of the accessibility of HIV-RNA assays for monitoring treated patients in resource-poor countries to detect early virological failure in order to preserve future therapeutic options...
  44. ncbi Foscarnet salvage therapy for patients with late-stage HIV disease and multiple drug resistance
    Ana Canestri
    Department des Maladies Infectieuses, Hopital Pitie Salpetriere, Paris, France
    Antivir Ther 11:561-6. 2006
    ..To evaluate the efficacy of foscarnet on HIV infection in patients with late-stage HIV disease and multiple drug resistance...
  45. pmc Similar evolution of cellular HIV-1 DNA level in darunavir/ritonavir monotherapy versus triple therapy in MONOI-ANRS136 trial over 96 weeks
    Sidonie Lambert-Niclot
    AP HP, Pitie Salpetriere Hospital, INSERM U 943 and Pierre et Marie Curie University Paris, Paris, France
    PLoS ONE 7:e41390. 2012
    ..Our objectives were to study the impact of 96 weeks of Darunavir/ritonavir monotherapy versus a triple standard combination on the HIV-1 blood reservoir and factors associated with HIV-1 plasma DNA at baseline in MONOI trial sub-study...
  46. pmc Low frequency of intermittent HIV-1 semen excretion in patients treated with darunavir-ritonavir at 600/100 milligrams twice a day plus two nucleoside reverse transcriptase inhibitors or monotherapy
    Sidonie Lambert-Niclot
    Department of Virology, Pitie Salpetriere Hospital, 83 Boulevard de l hopital, Paris, France
    Antimicrob Agents Chemother 54:4910-3. 2010
    ..The median darunavir seminal plasma concentration was close to the blood plasma free fraction, demonstrating a good penetration of darunavir into the male genital tract...
  47. ncbi Genetic diversity and drug resistance mutations in HIV type 1 from untreated patients in Bamako, Mali
    Anne Derache
    Department of Virology, Pitie Salpetriere Hospital, AP HP, EA 2387, Universite Pierre et Marie Curie, Paris, France
    Antivir Ther 12:123-9. 2007
    ..To determine the genetic diversity of HIV-1 reverse transcriptase (RT) and protease sequences and the presence of mutations linked to antiretroviral (ARV) resistance in treatment-naive, HIV-1-infected individuals living in Mali...
  48. ncbi Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients
    Yves Benhamou
    Service d Hepato Gastroenterologie, Hopital Pitie Salpetriere, Paris, France
    Hepatology 43:548-55. 2006
    ..In conclusion, this retrospective analysis demonstrates the efficacy of TDF against wild-type, presumed precore mutants and LAM-resistant HBV when used as a part of anti-retroviral therapy in HIV-coinfected patients...
  49. doi Role of genotype G hepatitis B virus mixed infection on the progression of hepatic fibrosis in HIV positive patients over 5 years of follow-up
    Ruxandra Călin
    AP HP, Service des Maladies Infectieuses, Hopital Pitie Salpetriere, Paris, France
    J Clin Virol 58:408-14. 2013
    ..The dynamic of liver disease in co-infected patients is important to understand for appropriate clinical management. Conflicting data surround the role played by genotype-G HBV (HBV-G) during the course of HIV co-infection...
  50. ncbi Relationship between mutations in HIV-1 RNase H domain and nucleoside reverse transcriptase inhibitors resistance mutations in naïve and pre-treated HIV infected patients
    Benedicte Roquebert
    Department of Virology, Pitié Salpêtrière Hospital and UPRES EA 2387, Universite Pierre et Marie Curie, Paris, France
    J Med Virol 79:207-11. 2007
    ..Mutations at position K558 were also associated with the number of thymidine analog mutations (TAMs). These results suggest that these mutations could play a role in NRTI resistance...
  51. ncbi Efficacy of a twice-daily antiretroviral regimen containing 100 mg ritonavir/400 mg indinavir in HIV-infected patients
    Jade Ghosn
    Department of Infectious Diseases, Inserm EO214, Pitie Salpetriere Hospital, Paris, France
    AIDS 17:209-14. 2003
    ....
  52. pmc Clinically relevant interpretation of genotype and relationship to plasma drug concentrations for resistance to saquinavir-ritonavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients
    Anne Genevieve Marcelin
    Department of Virology, Pitie Salpetriere Hospital, Paris, France
    Antimicrob Agents Chemother 48:4687-92. 2004
    ....
  53. doi Primary genotypic resistance of HIV-1 to CCR5 antagonists in CCR5 antagonist treatment-naive patients
    Cathia Soulie
    UMPC Université Paris 06, Paris, France
    AIDS 22:2212-4. 2008
    ..The V3 loop region was rather polymorphic, and 7.3% of patients showed viruses with combinations of mutations in V3 loop previously described to be involved in maraviroc resistance, a licensed CCR5 antagonist...
  54. pmc Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes
    Almoustapha Issiaka Maiga
    Laboratoire de Virologie, AP HP, Groupe Hospitalier Pitie Salpetriere, UPMC University Paris 06, INSERM U943, Paris, France
    Antimicrob Agents Chemother 54:728-33. 2010
    ..However, the transmission of drug-resistant viruses with Y181C in a non-B genetic background has a potential for impact on ETR susceptibility...
  55. pmc Antiretroviral therapy with a twice-daily regimen containing 400 milligrams of indinavir and 100 milligrams of ritonavir in human immunodeficiency virus type 1-infected women during pregnancy
    Jade Ghosn
    AP HP, Department of Infectious Diseases, Pitie Salpetriere Hospital, 47 Boulevard de l Hopital, 75013 Paris, France
    Antimicrob Agents Chemother 52:1542-4. 2008
    ..At delivery, 26 of 28 women on indinavir-ritonavir had HIV RNA levels of <200 copies/ml. No infant was HIV infected. These data are encouraging for the use of this combination for prevention of mother-to-child transmission of HIV...
  56. doi Antiretroviral combinations implicated in emergence of the L74I and L74V resistance mutations in HIV-1-infected patients
    Marc Wirden
    Department of Virology, Pitie Salpetriere Hospital, Paris, France
    AIDS 23:95-9. 2009
    ..This lack of knowledge has led to contradictory and confusing attitudes to L74I; although this mutation is not listed by the International AIDS Society - USA, it is increasingly included in several resistance algorithms...
  57. ncbi Highly multidrug-resistant HIV: clonal analysis and therapeutic strategies
    Eve Todesco
    Universite Pierre et Marie Curie, Paris 6, France
    J Antimicrob Chemother 68:2882-9. 2013
    ..We studied the distribution of resistance mutations at clonal level, and we analysed the therapeutic strategies used in such cases to achieve undetectable viraemia...
  58. doi Circulating interleukin-6 levels correlate with residual HIV viraemia and markers of immune dysfunction in treatment-controlled HIV-infected patients
    Jean Philippe Bastard
    UPMC Université de Paris 06, UMR_S938, INSERM, CdR Saint Antoine, Paris, France
    Antivir Ther 17:915-9. 2012
    ..Persistent low-level viral replication could be involved in this inflammatory state. We evaluated whether residual viral load (VL) correlated with the level of systemic inflammatory/immune markers in ART-controlled HIV-infected patients...
  59. doi Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients
    Claudine Duvivier
    AP HP, Groupe Hospitalier Pitie Salpetriere, Service de Maladies Infectieuses et Tropicales, Paris, France
    AIDS 23:817-24. 2009
    ..To evaluate the change in bone mineral density (BMD) at specific sites in patients initiating antiretroviral therapy in a substudy of the ANRS 121 trial...
  60. doi Natural evolution of CD4+ cell count in patients with CD4 >350 or >500  cells/mm3 at the time of diagnosis according to HIV-1 coreceptor tropism
    Cathia Soulie
    UMR S 943, Pierre et Marie Curie University, Paris, France
    J Med Virol 84:1853-6. 2012
    ....
  61. doi Dual raltegravir/etravirine combination in virologically suppressed HIV-1-infected patients on antiretroviral therapy
    Ruxandra Călin
    Infectious Diseases Department, Hopital Pitie Salpetriere, Paris, France
    Antivir Ther 17:1601-4. 2012
    ..The objective of this study was to evaluate the capacity of dual RAL/ETR therapy to maintain virological suppression in HIV-1 patients under effective antiretroviral therapy (ART)...
  62. doi E138K and M184I mutations in HIV-1 reverse transcriptase coemerge as a result of APOBEC3 editing in the absence of drug exposure
    Slim Fourati
    Université Pierre et Marie Curie Paris, Groupe Hospitalier Pitie Salpetriere, Laboratoire de Virologie, Paris, France
    AIDS 26:1619-24. 2012
    ..We show here that APOBEC3 proteins play a role in the emergence of these drug resistance mutations...
  63. doi Risk factors for raltegravir resistance development in clinical practice
    Isabelle Malet
    Laboratoire de Virologie, AP HP, Groupe Hospitalier Pitie Salpetriere, UPMC Université Pierre et Marie Curie, INSERM U943, Paris, France
    J Antimicrob Chemother 67:2494-500. 2012
    ..To investigate the best conditions of raltegravir use to avoid the selection of resistance mutations in the three main genetic pathways: 148, 155 and 143...
  64. doi E17A mutation in HIV-1 Vpr confers resistance to didanosine in association with thymidine analog mutations
    Slim Fourati
    Universite Pierre et Marie Curie, Paris, France
    Antiviral Res 93:167-74. 2012
    ..This process may play a role in the kinetics of appearance of drug resistance mutations under antiretroviral treatment...
  65. ncbi In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir
    Olivier Lada
    Virology, AP HP Pitié Salpêtrière Hospital, Paris, France
    Antivir Ther 9:353-63. 2004
    ..The excellent activity of TDF on lamivudine-resistant virus independently of the resistance mutation profile offers an interesting treatment alternative to HIV-HBV coinfected patients...
  66. doi Direct quantification of cell-associated HIV DNA in isolated rectal and blood memory CD4 T cells revealed their similar and low infection levels in long-term treated HIV-infected patients
    Benjamin Descours
    UPMC University Paris 06, INSERM, UMRs945, AP HP, Hopital Pitie Salpetriere, Laboratoire d Immunologie Cellulaire et Tissulaire, Paris, France
    J Acquir Immune Defic Syndr 62:255-9. 2013
    ....
  67. doi Pitfalls of HIV genotypic tropism testing after treatment interruption
    Marc Wirden
    Universite Pierre et Marie Curie, Paris 6, France
    J Antimicrob Chemother 68:188-9. 2013
    ..The results of HIV genotypic tropism testing in such a context remain unknown...
  68. doi Influence of interferon-based therapy on liver fibrosis progression in HIV/HCV coinfected patients: a retrospective repeated liver biopsy analysis
    Patrick Ingiliz
    Hepatology Department, Pitie Salpetriere Hospital, Paris, France
    J Hepatol 56:49-54. 2012
    ..The course of the disease is determined by the rapidity of liver fibrosis progression (LFP). The influence of interferon on LFP in coinfected patients has yet not been evaluated by comparative liver biopsies...
  69. ncbi Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients
    Aurélie Barrail-Tran
    AP HP, Hospital Bicetre, Paris, France
    AIDS 24:2581-3. 2010
    ..118 and 3837 vs. 2241 ng/ml) and darunavir area under the curve (AUC(12h)) (50 083 vs. 36 277 ng h/ml). All pharmacokinetic parameters appeared to be highly variable regardless to the addition of etravirine...
  70. ncbi Therapeutic immunization with a human immunodeficiency virus (HIV) type 1-recombinant canarypox vaccine in chronically HIV-infected patients: The Vacciter Study (ANRS 094)
    Roland Tubiana
    Departement des Maladies Infectieuses et Tropicales, INSERM E0214, Hopital Pitie Salpetriere, Paris, France
    Vaccine 23:4292-301. 2005
    ..Detection of such LPR response at the time of treatment interruption was significantly associated with the probability of remaining off therapy. These results provide rationale for future randomized trials exploring this strategy...
  71. pmc Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients
    Anne Genevieve Marcelin
    Department of Virology, INSERM EMI 0214, Bichat Claude Bernard Hospital, Paris, France
    Antimicrob Agents Chemother 47:594-600. 2003
    ....
  72. ncbi Modulation of interleukin-7 receptor expression characterizes differentiation of CD8 T cells specific for HIV, EBV and CMV
    François Boutboul
    Laboratoire d Immunologie Cellulaire, Hopital Pitie Salpetriere, Universite Pierre et Marie Curie, Paris, France
    AIDS 19:1981-6. 2005
    ....
  73. pmc Repertoire, diversity, and differentiation of specific CD8 T cells are associated with immune protection against human cytomegalovirus disease
    Karim Sacre
    Laboratoire d Immunologie Cellulaire et Tissulaire, INSERM U543, Hopital Pitie Salpetriere, Universite Pierre et Marie Curie, 75013 Paris, France
    J Exp Med 201:1999-2010. 2005
    ....
  74. doi Cellular CD4 T cell responses to the diphtheria-derived carrier protein of conjugated pneumococcal vaccine and antibody response to pneumococcal vaccination in HIV-infected adults
    Claire Rabian
    Laboratoire d Immunologie et d Histocompatibilité, St Louis Hospital, Paris, France
    Clin Infect Dis 50:1174-83. 2010
    ..CD4 T cell responses specific to the diphtheria-derived carrier protein CRM(197) were evaluated...
  75. ncbi Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients: 24-week results of POWER 3
    Jean Michel Molina
    Assistance Publique Hopitaux de Paris, Department of Infectious Diseases, Hopital St Louis, Paris, France
    J Acquir Immune Defic Syndr 46:24-31. 2007
    ..To examine the efficacy and safety of the selected darunavir/r dose further, additional patients were analyzed...
  76. doi Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial
    Nathalie de Castro
    Department of Infectious Diseases, Assistance Publique Hopitaux de Paris, Saint Louis Hospital and University of Paris VII Denis Diderot, Paris, France
    Clin Infect Dis 49:1259-67. 2009
    ..We conducted a prospective, randomized, open-label trial to compare the antiviral efficacy and safety of a switch to raltegravir with the efficacy and safety of continuing enfuvirtide...
  77. doi Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy
    Ana Canestri
    Hopital Pitie Salpetriere, Paris, France
    Clin Infect Dis 50:773-8. 2010
    ..We report data on 11 patients with neurological symptoms and human immunodeficiency virus (HIV) cerebrospinal fluid (CSF) viremia contrasting with suppressed plasma HIV RNA during receipt of combined antiretroviral therapy...
  78. doi Incidence and risk factors of thrombocytopenia in patients receiving intermittent antiretroviral therapy: a substudy of the ANRS 106-window trial
    Marie Anne Bouldouyre
    Department of Infectious Diseases, Hopital Saint Louis, Assistance Publique Hôpitaux de Paris and University of Paris Diderot Paris 7, France
    J Acquir Immune Defic Syndr 52:531-7. 2009
    ..Incidence and risk factors for thrombocytopenia in patients discontinuing highly active antiretroviral therapy (HAART) have not been fully investigated...
  79. doi Prevalence of resistance mutations related to integrase inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated patients
    Isabelle Malet
    Laboratoire de Virologie, AP HP, Groupe Hospitalier Pitie Salpetriere, UPMC Universite Paris 06, INSERM U943, Paris, France
    J Antimicrob Chemother 66:1481-3. 2011
    ....
  80. ncbi Decreased frequencies of virus-specific T helper type 1 cells during interferon alpha plus ribavirin treatment in HIV-hepatitis C virus co-infection
    Nadia Alatrakchi
    Laboratoire d Immunologie Cellulaire et Tissulaire INSERM U543, Centre Hospitalier Universitaire Pitie Salpetriere, Paris, France
    AIDS 18:121-3. 2004
    ..This suggests that IFN+R therapy might compromise virus-specific immune defenses in immunosuppressed patients...
  81. doi Higher efficacy of nevirapine than efavirenz to achieve HIV-1 plasma viral load below 1 copy/ml
    Stéphanie Haïm-Boukobza
    Laboratoire de Virologie, AP HP, Groupe Hospitalier Pitie Salpetriere, UPMC Univ Paris, Paris, France
    AIDS 25:341-4. 2011
    ..To compare the level of HIV-1 residual viremia, defined by a viral load below 50 copies/ml in patients receiving a tenofovir/emtricitabine and nevirapine (NVP) or efavirenz (EFV)-containing regimen...
  82. doi Immune and virological benefits of 10 years of permanent viral control with antiretroviral therapy
    Amelie Guihot
    UPMC Univ Paris 06, INSERM, UMR945, AP HP, Laboratoire d Immunologie Cellulaire et Tissulaire, Hopital Pitie Salpetriere, Paris, France
    AIDS 24:614-7. 2010
    ..Long-term and efficient antiretroviral therapy provides continuous benefits both on the immune system and on the HIV reservoirs...
  83. doi Six-year follow-up of hepatitis B surface antigen concentrations in tenofovir disoproxil fumarate treated HIV-HBV-coinfected patients
    Vincent Thibault
    Virology Laboratory, Hopital Pitie Salpetriere, Assistance Publique, Paris, France
    Antivir Ther 16:199-205. 2011
    ..Our main objective was to study the kinetics of HBsAg level in HIV-HBV-coinfected patients with undetectable HBV DNA load under treatment containing tenofovir disoproxil fumarate (TDF)...
  84. doi Liver damage underlying unexplained transaminase elevation in human immunodeficiency virus-1 mono-infected patients on antiretroviral therapy
    Patrick Ingiliz
    Hepatology Department, AP HP, GH Pitié Salpétrière, Paris, France
    Hepatology 49:436-42. 2009
    ..Conclusions: HIV-infected patients on combined antiretroviral therapy with chronic transaminase elevation of unknown origin have a high rate of liver lesions, mostly consistent with NASH related to insulin resistance...